Reducing the toxicity of cancer therapy: recognizing needs, taking action
Reducing the toxicity of cancer therapy: recognizing needs, taking action
复制标题
DOI：
10.1038/nrclinonc.2012.99
复制
发表时间：
2012-08-01
影响因子：
78.8
通讯作者：
Skillings, Jamey
中科院分区：
文献类型：
--
作者：
Cleeland, Charles S.;Allen, Jeff D.;Skillings, Jamey
我们对癌症生物学的理解以及这些知识在癌症治疗中的应用已经大大超过了我们对治疗产生的症状和毒性作用的生物学基础的了解。治疗的这些不良反应会给患者及其家属造成严重的不适和痛苦，限制治疗耐受性，并可能在治疗后生存期内无限期持续。尽管有这些问题，很少有研究工作是针对记录这些影响的性质。同样，在药物开发竞技场中，为确定或开发可能预防或减少毒性的治疗方法所做的努力有限。召集了一个由临床医生和研究人员以及倡导团体、联邦机构和制药业代表组成的小组，以确定癌症治疗毒性研究的差距，并为未来的行动提供方向。该小组以协调多学科努力为重点，提出了一项战略，以增加对该领域的供资，并制定一项连贯一致的研究议程。克利兰角S.等人，Nat. Rev. Clin. Oncol. 9，471-478（2012）; 2012年7月3日在线发表; doi：10.1038/nrclinonc.2012.99
Our understanding of the biology of cancer and the application of this knowledge to cancer treatment has greatly outpaced what we know of the biology underlying the symptoms and toxic effects that therapies produce. These adverse effects of therapy cause substantial discomfort and distress to patients and their families, limit treatment tolerability and can persist indefinitely in post-treatment survivorship. Despite these concerns, little research effort is targeted at documenting the nature of these effects. Similarly, limited efforts are being made in the drug-development arena to identify or develop treatments that might prevent or reduce toxicities. A panel of clinicians and researchers as well as representatives from advocacy groups, federal agencies and the pharmaceutical industry was convened to identify gaps in cancer treatment toxicity research and to provide direction for future action. With an emphasis on coordinating multidisciplinary efforts, this panel has presented a strategy to increase funding for the field and develop a coherent research agenda. Cleeland, C. S. et al. Nat. Rev. Clin. Oncol. 9, 471-478 (2012); published online 3 July 2012; doi:10.1038/nrclinonc.2012.99